Meningovascular neurosyphilis
MONDO:0000336A tertiary neurosyphilis that results in inflammation located in arteries of the brain or located in arteries of spinal cord. The infection has symptom headache, has symptom neck stiffness, has symptom dizziness, has symptom behavioral abnormalities, has symptom poor concentration, has symptom memory loss, has symptom lassitude, has symptom insomnia, has symptom blurred vision, has symptom weakness and wasting of shoulder-girdle and arm muscles, has symptom slowly progressive leg weakness with urinary or fecal incontinence or both, and has symptom paralysis of the legs due to thrombosis of spinal arteries.
9 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New antibiotic cocktail aimed at Drug-Resistant infections in babies
Disease control Recruiting nowThis study tests a combination of two antibiotics, aztreonam and avibactam, in newborns and infants up to 9 months old who have serious infections caused by gram-negative bacteria. The trial has two parts: one to see how a single dose moves through the body, and another to test m…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Double antibiotic attack: could a Two-Drug combo beat severe infections faster?
Disease control Recruiting nowThis study tests whether adding a second antibiotic (fosfomycin) to the standard antibiotic (ceftazidime) helps people with severe gram-negative infections recover faster. About 100 hospitalized adults will be randomly assigned to get either the combo or the standard drug plus a …
Phase: PHASE3 • Sponsor: Angela HUTTNER • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Real-World watch: is zavicefta safe for tough infections?
Knowledge-focused Recruiting nowThis study observes 600 patients in Korea who receive Zavicefta for complicated abdominal or urinary tract infections or hospital-acquired pneumonia. Researchers track side effects and how well the drug works. It is required by Korean regulators to ensure the drug's safety after …
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:53 UTC